Hussein Tawbi, MD, PhD, introduces an upcoming Targeted Oncology Case-Based Peer Perspectives program on advancements in the ...

Findings presented at IMS 2023 suggest multi-specific strategies will be needed to avoid the antigen loss created by ...

After results presented at IMS 2023 , further evaluation of strength building and walking in patients with multiple myeloma ...

John M. Burke, MD, discusses how Bruton tyrosine kinase inhibitors have demonstrated unexpected promise in treating ...

IDE161 now has 2 fast track designations from the FDA for patients with breast cancer and ovarian cancer. The agent continues ...

Daniel P. Petrylak, MD, discusses background and findings from the phase 3 KEYNOTE-921 study of pembrolizumab plus docetaxel vs placebo plus docetaxel in patients with metastatic castration-resistant ...

Results of the phase 3 MIRASOL study evaluating mirvetuximab soravtansine for platinum-resistant ovarian cancer will be announced at an upcoming meeting. Mirvetuximab soravtansine-gynx (Elahere) has ...

Topline results from MARIPOSA reveal a survival advantage with amivantamab plus lazertinib vs osimertinib in patients with EGFR-mutant non–small cell lung cancer. Additional follow-up is planned.

Researchers presented updated results from longer-term follow-up studies of GC012F for newly-diagnosed multiple myeloma ...

In the first article of a 2-part series, Amrita Krishnan, MD, discusses the two recent trials that show talquetamab’s promise ...

In an interview with Targeted Oncology, Richard S. Finn, MD, discussed his ILCA Annual Conference 2023 presentation on ...

During a Targeted Oncology™ Community Case Forum event in partnership with The Arizona Clinical Oncology Society, Alan H.